Westend Capital Management’s Aratana Therapeutics, Inc. PETX Stock Holding History

Westend Capital Management’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-73,900	Closed	-$467K	–	71
2016 Q2	$467K	Sell	73,900 -49,290	-40%	-$317K	0.68%	42
2016 Q1	$680K	Buy	123,190 +33,410	+37%	+$126K	0.93%	38
2015 Q4	$501K	Sell	89,780 -34,755	-28%	-$230K	0.69%	35
2015 Q3	$912K	Buy	124,535 +34,000	+38%	+$575K	1.16%	35
2015 Q2	$1.38M	Buy	90,535 +1,425	+2%	+$20.6K	1.61%	30
2015 Q1	$1.44M	Buy	89,110 +13,900	+18%	+$247K	1.69%	27
2014 Q4	$1.34M	Buy	+75,210	New	+$937K	1.55%	32

Other funds holding PETX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Westend Capital Management's PETX Position: Q3 2016 in Review

Westend Capital Management sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2016, closing a stake of 73,900 shares — an estimated $467K sold.

Westend Capital Management first reported a position in PETX in Q4 2014 and held it in 7 quarters. The position peaked at $1.44M in Q1 2015. 128 funds tracked by Wall St. Rank hold PETX as of Q3 2016.

Westend Capital Management reported no remaining Aratana Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
Westend Capital Management sold 73,900 Aratana Therapeutics, Inc. shares in Q3 2016, an estimated $467K.
Westend Capital Management first reported a position in Aratana Therapeutics, Inc. in Q4 2014 and held it in 7 quarters.
Westend Capital Management's Aratana Therapeutics, Inc. position peaked at $1.44M in Q1 2015.
128 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2016.

Based on Westend Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.